https://www.pharmaceutical-technology.com/data-insights/anifrolumab-astrazeneca-vitiligo-likelihood-of-approval/
Anifrolumab by AstraZeneca for Vitiligo: Likelihood of Approval
Jan 21, 2025 - Anifrolumab is under clinical development by AstraZeneca and currently in Phase II for Vitiligo.
anifrolumabastrazenecavitiligolikelihoodapproval
https://www.cigna.com/knowledge-center/hw/medications/anifrolumab-fnia-injection-a621046
Anifrolumab-fnia Injection | Cigna
(an" i frol' ue mab)
anifrolumab fniainjectioncigna
https://www.fiercebiotech.com/biotech/astrazeneca-plans-2020-filing-for-anifrolumab-lupus
AstraZeneca plans 2020 filing for anifrolumab in lupus | Fierce Biotech
Nov 12, 2019 - AstraZeneca is planning to file for approval of anifrolumab in systemic lupus erythematosus (SLE) in the second half of next year.
astrazenecaplans2020filinganifrolumab
https://www.servicesaustralia.gov.au/pb365
Systemic lupus erythematosus - anifrolumab - initial authority application form (PB365) - Services...
Use this form to apply for initial PBS-subsidised treatment with anifrolumab for systemic lupus erythematosus.
systemic lupus erythematosusapplication formanifrolumabinitialauthority
https://www.arthritis.org/health-wellness/treatment/treatment-plan/disease-management/new-drug-approved-for-lupus
New Lupus Treatment Medication: Anifrolumab (Saphnelo) | Arthritis Foundation
Aug 12, 2021 - A new biologic for systemic lupus erythematosus may help reduce corticosteroid use.
lupus treatmentnewmedicationanifrolumabsaphnelo
https://rheumatology.org/patients/anifrolumab-fnia-saphnelo
Anifrolumab-fnia (Saphnelo) | American College of Rheumatology
Information for patients and caregivers about Anifrolumab-fnia (Saphnelo), such as usages, common dosages, safety tips, and possible side effects.
anifrolumab fniaamerican collegesaphnelorheumatology